Cardiff Oncology , Inc.

The momentum for this stock is not very good. Cardiff Oncology , Inc. is not a good value stock. Cardiff Oncology , Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Cardiff Oncology , Inc..

News

Craig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)

TipRanks Financial Blog Craig-Hallum analyst Albert Lowe maintained a Buy rating on Cardiff Oncology (CRDF - Research Report) today and set a price target of $8.00. The co...\n more…

Craig Hallum Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF)

Zolmax Investment analysts at Craig Hallum started coverage on shares of Cardiff Oncology (NASDAQ:CRDF - Get Free Report) in a report issued on Friday, MarketBeat Ratings reports. The brokerage set a "buy...\n more…

Cardiff Oncology initiated with bullish view at Craig-Hallum

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cardiff Oncology (NASDAQ:CRDF) versus CERo Therapeutics (NASDAQ:CERO) Financial Contrast

Ticker Report Cardiff Oncology (NASDAQ:CRDF - Get Free Report) and CERo Therapeutics (NASDAQ:CERO - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two...\n more…

Assenagon Asset Management S.A. Buys 962,940 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Ticker Report Assenagon Asset Management S.A. increased its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 380.6% in the second quarter, according to the company in its most recent Form 13F filing...\n more…

Cardiff Oncology (NASDAQ:CRDF) and Agenus (NASDAQ:AGEN) Head to Head Survey

Ticker Report Cardiff Oncology (NASDAQ:CRDF - Get Free Report) and Agenus (NASDAQ:AGEN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies...\n more…